INVA
INVA
NASDAQ · Pharmaceuticals

Innoviva Inc

$22.88
+0.08 (+0.35%)
As of May 9, 1:33 AM ET ·
Financial Highlights (FY 2026)
Revenue
359.60M
Net Income
237.06M
Gross Margin
74.8%
Profit Margin
65.9%
Rev Growth
+7.5%
D/E Ratio
0.22
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 74.8% 74.8% 67.3% 67.3%
Operating Margin 39.8% 35.8% 36.7% 43.7%
Profit Margin 65.9% 62.6% 33.9% 33.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 359.60M 334.57M 296.49M 325.02M
Gross Profit 268.98M 250.26M 199.68M 218.90M
Operating Income 143.15M 119.87M 108.77M 141.90M
Net Income 237.06M 198.50M 100.45M 107.69M
Gross Margin 74.8% 74.8% 67.3% 67.3%
Operating Margin 39.8% 35.8% 36.7% 43.7%
Profit Margin 65.9% 62.6% 33.9% 33.1%
Rev Growth +7.5% +7.5% +12.4% +2.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 152.69M 152.69M 569.66M 644.56M
Total Equity 695.00M 695.00M 1.17B 1.19B
D/E Ratio 0.22 0.22 0.49 0.54
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 152.84M 135.10M 161.71M 177.91M
Free Cash Flow 84.32M 106.96M